Accent Therapeutics, Inc.

Accent is developing oncology-focused, small molecule therapies in the emerging field of RNA modification.

[Accent Therapeutics, Inc. @accent_tx]

Happening now: our #AACR23 presentation on the compelling evidence supporting targeted inhibition of DHX9 as a novel therapeutic modality in MSI-H colorectal cancer. Click here to learn more: https://t.co/ahXTcQRMuA

[Accent Therapeutics, Inc. @accent_tx]

If you're at the 2023 @GordonConf on RNA Editing this week, you won't want to miss our poster "Discovery of Small Molecule Inhibitors of #ADAR1"!

[Accent Therapeutics, Inc. @accent_tx]

Thoughtfully building and scaling compound management is essential to efficient, highly-integrated small molecule #drugdiscovery and development - learn more about our approach as shared at #SLAS2023

[Accent Therapeutics, Inc. @accent_tx]

If you'll be at #SLAS2023, don't miss the chance to see two exciting posters from #TeamAccent!

[Accent Therapeutics, Inc. @accent_tx]

Congratulations to our founder, Chuan He, on being named a #WolfPrize2023 Laureate in Chemistry for "discovering reversible RNA methylation and its role in the regulation of gene expression"!

[Wolf Prize @WolfPrize_]

Congratulations to Chuan He, 2023 Wolf Prize laureate in Chemistry!
@UChiChemistry @UChicago

[Accent Therapeutics, Inc. @accent_tx]

We are delighted to welcome Serena Silver to #TeamAccent as our Vice President of Biology! https://t.co/SFULDUQ9OG #lifesciences #Leaders

[Accent Therapeutics, Inc. @accent_tx]

Congratulations to our scientific advisor and thought partner, Professor Karen Allen!

[ACS Biochem and ChemBio @acsbiol]

The DBC is pleased to announce that Prof. Karen Allen of Boston University is the winner of the inaugural Abeles and Jencks Award for the Chemistry of Biological Processes for 2022! https://t.co/1pGK6AYCYv
@BUChemistry @allenlab @AmerChemSociety

[Accent Therapeutics, Inc. @accent_tx]

DYK that #TeamAccent is proudly 50% female? Today our hardworking team celebrates #WomenInScience Day and all of the amazing, difference-making #WomenInSTEM!

[Accent Therapeutics, Inc. @accent_tx]

Today, #WorldCancerDay, and every day, we join the @uicc in promoting greater understanding and recognition of the inequities in cancer care around the globe. Together, we must #CloseTheCareGap.

[Accent Therapeutics, Inc. @accent_tx]

We are thrilled to welcome Stephen Blakemore to #TeamAccent as our Vice President of Translational Medicine! https://t.co/SFULDUyyq6 #lifesciences #leaders

[Accent Therapeutics, Inc. @accent_tx]

Congratulations to our co-founder and thought partner, Chuan He!

[ACS Publications Bio & Med Chem Content @ACSBioMed]

Introducing Chuan He, the new Editor-In-Chief of ACS Chemical Biology! Read about his vision for the journal, his current research interests, and his advice for young scientists here- https://t.co/6PsSKUjgcG

[Accent Therapeutics, Inc. @accent_tx]

Coming up! Our Vice President of Molecular Discovery, Ann Boriack-Sjodin, presents at the 4th Annual @RNA_TDD Summit on December 9th!
https://t.co/bYwCYRy40x

[Accent Therapeutics, Inc. @accent_tx]

We are pleased to entrust our #METTL3 program to the innovative team at @IpsenGroup and delighted to share the news of this partnership! #RMPs #RNAModification

https://t.co/4AlKdSYtZr

[Biochemistry @BiochemistryACS]

Our issue this week includes work by Robert A. Copeland, Steve Bourgault, Junichi Taira, Shogo Nakano, Sohei Ito, @clvizcarra and more. Check out issue 29 now at https://t.co/RgRrXWnt4n @accent_tx @ChimieUqam @kyutech @Barnard_Chem

[Accent Therapeutics, Inc. @accent_tx]

If you're looking for inspiration on this #InnovationWednesday - you won't want to miss "Chance Favors the Perplexed Mind" out today in @BiochemistryACS from our own Bob Copeland! https://t.co/rheakBOeCd

[Accent Therapeutics, Inc. @accent_tx]

A "must add" for your holiday weekend reading list - our own Bob Copeland's Expert Opinion on the importance and evolution of the drug-target residence time model! Happy #PublicationFriday!
https://t.co/ol4451nF6e

[Accent Therapeutics, Inc. @accent_tx]

A true visionary, oncology thought leader and dedicated patient advocate - José Baselga leaves a powerful and enduring legacy. We are deeply saddened by the news of his passing. Our heartfelt condolences to his family, friends and colleagues.

[AstraZeneca @AstraZeneca]

We are deeply saddened by the news that José Baselga, EVP Oncology R&D, has passed away. An outstanding scientific leader, José leaves a lasting legacy in the scientific community and here at AstraZeneca. We send our condolences to his family. https://t.co/hiVTYIkdKm

[Accent Therapeutics, Inc. @accent_tx]

On #EmployeeAppreciation Day, and every day, we say THANK YOU to each and every member of #TeamAccent! Your creativity, compassion, teamwork and drive are an inspiration!

[Accent Therapeutics, Inc. @accent_tx]

Coming up! On March 11th, our President & CSO, Bob Copeland, joins in a discussion on the progress, #therapeutic potential and challenges of targeting #mRNA biology, part of the @demycolton Virtual Salon Series https://t.co/xhbxP7Lx8S

[Chemistry World @ChemistryWorld]

‘We only have three problems and they’re delivery, delivery, delivery’ – Rachel Brazil explores a new route to treating disease

https://t.co/Et2yuKiyQK